Cue Biopharma, Inc. (CUE)
CUE Stock Price Chart
Explore Cue Biopharma, Inc. interactive price chart. Choose custom timeframes to analyze CUE price movements and trends.
CUE Company Profile
Discover essential business fundamentals and corporate details for Cue Biopharma, Inc. (CUE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Jan 2018
Employees
41.00
Website
https://www.cuebiopharma.comCEO
Daniel R. Passeri
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
CUE Financial Timeline
Browse a chronological timeline of Cue Biopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.10.
Earnings released on 12 Aug 2025
EPS came in at -$0.09 surpassing the estimated -$0.13 by +30.77%, while revenue for the quarter reached $2.95M , beating expectations by +29.01%.
Earnings released on 12 May 2025
EPS came in at -$0.17 falling short of the estimated -$0.14 by -21.43%, while revenue for the quarter reached $421.00K , missing expectations by -66.79%.
Earnings released on 31 Mar 2025
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $1.58M , missing expectations by -7.36%.
Earnings released on 14 Nov 2024
EPS came in at -$0.17 surpassing the estimated -$0.20 by +15.00%, while revenue for the quarter reached $3.34M , beating expectations by +96.10%.
Earnings released on 14 Aug 2024
EPS came in at -$0.20 surpassing the estimated -$0.29 by +31.03%, while revenue for the quarter reached $2.66M , beating expectations by +106.05%.
Earnings released on 9 May 2024
EPS came in at -$0.25 surpassing the estimated -$0.30 by +16.67%, while revenue for the quarter reached $1.72M , beating expectations by +41.90%.
Earnings released on 8 Apr 2024
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $1.82M , beating expectations by +82.10%.
Earnings released on 9 Nov 2023
EPS came in at -$0.24 surpassing the estimated -$0.30 by +20.00%, while revenue for the quarter reached $2.10M , missing expectations by -6.25%.
Earnings released on 8 Aug 2023
EPS came in at -$0.29 surpassing the estimated -$0.30 by +3.33%, while revenue for the quarter reached $1.38M , beating expectations by +51.87%.
Earnings released on 9 May 2023
EPS came in at -$0.29 surpassing the estimated -$0.33 by +12.12%, while revenue for the quarter reached $187.00K , missing expectations by -90.41%.
Earnings released on 21 Mar 2023
EPS came in at -$0.37 falling short of the estimated -$0.32 by -15.62%, while revenue for the quarter reached $151.23K , beating expectations by +51.23%.
Earnings released on 14 Nov 2022
EPS came in at -$0.31 surpassing the estimated -$0.38 by +18.42%, while revenue for the quarter reached $68.00K , missing expectations by -86.76%.
Earnings released on 4 Aug 2022
EPS came in at -$0.37 surpassing the estimated -$0.42 by +11.90%, while revenue for the quarter reached $26.00K , missing expectations by -97.70%.
Earnings released on 10 May 2022
EPS came in at -$0.44 falling short of the estimated -$0.43 by -2.33%, while revenue for the quarter reached $1.00M , missing expectations by -67.26%.
Earnings released on 16 Mar 2022
EPS came in at -$0.26 falling short of the estimated -$0.25 by -4.00%, while revenue for the quarter reached $8.25M , beating expectations by +624.70%.
Earnings released on 9 Nov 2021
EPS came in at -$0.41 falling short of the estimated -$0.39 by -5.13%, while revenue for the quarter reached $2.40M , beating expectations by +16.83%.
Earnings released on 9 Aug 2021
EPS came in at -$0.33 surpassing the estimated -$0.42 by +21.43%, while revenue for the quarter reached $2.74M , meeting expectations.
Earnings released on 17 May 2021
EPS came in at -$0.41 falling short of the estimated -$0.37 by -10.81%, while revenue for the quarter reached $1.55M , beating expectations by +8.57%.
Earnings released on 16 Mar 2021
EPS came in at -$0.37 falling short of the estimated -$0.33 by -12.12%, while revenue for the quarter reached $475.33K .
Earnings released on 17 Nov 2020
EPS came in at -$0.34 surpassing the estimated -$0.37 by +8.11%, while revenue for the quarter reached $704.00K .
CUE Stock Performance
Access detailed CUE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.